These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 23991729)

  • 1. Lung cancer biomarkers: present status and future developments.
    Cagle PT; Allen TC; Olsen RJ
    Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The classification of lung carcinoma: time to change the morphology-based approach?
    Pelosi G; Sonzogni A; Viale G
    Int J Surg Pathol; 2010 Jun; 18(3):161-72. PubMed ID: 20460313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular prognostication of non-small cell lung cancer.
    Tsao MS; Jablons DM
    Semin Thorac Cardiovasc Surg; 2013; 25(1):4-7. PubMed ID: 23800523
    [No Abstract]   [Full Text] [Related]  

  • 4. Lung cancer genotype-based therapy and predictive biomarkers: present and future.
    Cagle PT; Allen TC
    Arch Pathol Lab Med; 2012 Dec; 136(12):1482-91. PubMed ID: 23194040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What's new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements.
    Cooper WA; O'toole S; Boyer M; Horvath L; Mahar A
    Pathology; 2011 Feb; 43(2):103-15. PubMed ID: 21233671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers of DNA repair and related pathways: significance in non-small cell lung cancer.
    Rothschild SI; Gautschi O; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2011 Mar; 23(2):150-7. PubMed ID: 21119513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine.
    Pilotto S; Peretti U; Novello S; Rossi G; Milella M; Giaj Levra M; Ciuffreda L; Massari F; Brunelli M; Tortora G; Bria E
    Expert Opin Pharmacother; 2013 Apr; 14(5):597-608. PubMed ID: 23472711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer.
    Kulesza P; Ramchandran K; Patel JD
    Am J Clin Pathol; 2011 Aug; 136(2):228-38. PubMed ID: 21757595
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for molecular staging of non-small-cell lung cancer from genomic alterations.
    Tomaszek SC; Huebner M; Wigle DA
    Expert Rev Respir Med; 2010 Aug; 4(4):499-508. PubMed ID: 20658911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Template for reporting results of biomarker testing of specimens from patients with non-small cell carcinoma of the lung.
    Cagle PT; Sholl LM; Lindeman NI; Alsabeh R; Divaris DX; Foulis P; Lee G; Neal JW; Nowak JA; Yu PP;
    Arch Pathol Lab Med; 2014 Feb; 138(2):171-4. PubMed ID: 23808401
    [No Abstract]   [Full Text] [Related]  

  • 11. Molecular pathology of non-small cell lung cancer: a practical guide.
    Aisner DL; Marshall CB
    Am J Clin Pathol; 2012 Sep; 138(3):332-46. PubMed ID: 22912349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of lung carcinoma: identifying clinically useful tumor markers for diagnosis and prognosis.
    Dacic S
    Expert Rev Mol Diagn; 2007 Jan; 7(1):77-86. PubMed ID: 17187486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of targeted therapy in non-small cell lung cancer.
    Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
    Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumor heterogeneity and chemotherapy-induced changes in EGFR status in non-small cell lung cancer.
    Jakobsen JN; Sørensen JB
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):289-99. PubMed ID: 22130585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue sampling in lung cancer: a review in light of the MERIT experience.
    Reck M; Hermes A; Tan EH; Felip E; Klughammer B; Baselga J
    Lung Cancer; 2011 Oct; 74(1):1-6. PubMed ID: 21658788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and management of non-small cell lung cancer.
    Herbst RS; Morgensztern D; Boshoff C
    Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How today's developments in the treatment of non-small cell lung cancer will change tomorrow's standards of care.
    Kris MG
    Oncologist; 2005 Oct; 10 Suppl 2():23-9. PubMed ID: 16272456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chondrolectin is a novel diagnostic biomarker and a therapeutic target for lung cancer.
    Masuda K; Takano A; Oshita H; Akiyama H; Tsuchiya E; Kohno N; Nakamura Y; Daigo Y
    Clin Cancer Res; 2011 Dec; 17(24):7712-22. PubMed ID: 22016508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients.
    Park HS; Lee JK; Kim DW; Kulig K; Kim TM; Lee SH; Jeon YK; Chung DH; Heo DS
    Lung Cancer; 2012 Aug; 77(2):288-92. PubMed ID: 22465695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized medicine for lung cancer: new challenges for pathology.
    Kerr KM
    Histopathology; 2012 Mar; 60(4):531-46. PubMed ID: 21916947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.